NASDAQ: CRMDCormedix Inc Stock
$7.93+0.11 (+1.41%)
Updated May 20, 2026
CRMD Price
$7.93
Fair Value Price
N/A
Market Cap
$622.12M
52 Week Low
$6.13
52 Week High
$17.43
P/E
3.42x
P/B
1.42x
P/S
1.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$400.05M
Earnings
$181.01M
Gross Margin
85.8%
Operating Margin
46.94%
Profit Margin
45.2%
Debt to Equity
0.87
Operating Cash Flow
$198M
Beta
1.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CRMD Overview
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRMD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CRMD
Ranked#132 of 463
Ranked#132 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $239.01 | A | |
| $49.90 | A | |
| $2.01 | A |
Be the first to know about important CRMD news, forecast changes, insider trades & much more!
CRMD News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRMD is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRMD is good value based on its earnings relative to its share price (3.42x), compared to the US market average (21.02x)
P/E vs Market Valuation
CRMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more CRMD due diligence checks available for Premium users.
Valuation
CRMD fair value
Fair Value of CRMD stock based on Discounted Cash Flow (DCF)
Price
$7.93
Fair Value
-$0.32
Undervalued by
2,540.33%
CRMD is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CRMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
3.42x
Industry
17.68x
Market
21.02x
CRMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CRMD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CRMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.42x
Industry
4.85x
CRMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRMD's financial health
Profit margin
Revenue
$127.4M
Net Income
$38.6M
Profit Margin
30.3%
CRMD's Earnings (EBIT) of $187.79M... subscribe to Premium to read more.
Interest Coverage Financials
CRMD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$815.6M
Liabilities
$378.6M
Debt to equity
0.87
CRMD's short-term assets ($383.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRMD's short-term assets ($383.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRMD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CRMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$42.4M
Investing
$3.0M
Financing
-$12.1M
CRMD's operating cash flow ($197.69M)... subscribe to Premium to read more.
Debt Coverage Financials
CRMD vs Biotech Stocks
Cormedix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.